At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,131 enrolled
Drug / intervention
AZD7442 +1 moredrug
Likely dose
AZD7442 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19
In Brief
A Phase 3 clinical trial evaluating AZD7442 and Placebo for COVID-19. Completed, enrolled 1,131 participants across 57 sites in 2 countries.
Detailed Summary
This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited Kingdom, United States
CollaboratorsIQVIA Pty Ltd
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionApr 2021
Study CompletionJul 2022
TodayJul 2026
First PostedNov 12, 2020
Enrollment StartDec 2, 2020
Primary CompletionApr 7, 2021
Study CompletionJul 25, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.6 years ago
Interventions
AZD7442drug
Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
Placebodrug
Single dose (× 2 IM injections) of saline placebo on Day 1.